Vir Biotechnology Inc VIR
News
Vir Biotechnology Announces Proposed Public Offering
Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data
Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta
Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD’s The Liver Meeting® 2026 and Host Investor Conference Call
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Vir Biotechnology to Participate in the Jefferies 2026 London Healthcare Conference
Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors
Vir Biotechnology to Host Conference Call for Third Quarter 2026 Financial Results
Vir Biotechnology Shares Jump on Gilead Cancer Collaboration
Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors
Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer
Vir Biotechnology Appoints David Liu as Chief Medical Officer
Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026
Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Vir Biotechnology, Astellas in $335 Million Licensing Deal for Prostate Cancer Treatment
